Alex Delaney-Gesing 

home

authors

alex-delaney-gesing


Dilraj Grewal, MD, associate professor of ophthalmology at Duke Eye Center/ director of grading at the Duke Reading Center, speaks with 

' David Hutton on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during the Inflammatory and Infectious Diseases Symposium of the virtual 2020 American Society of Retina Specialists (ASRS) meeting.

Videos

Dilraj Grewal, MD, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during ASRS 2020. 

Evaluating 3-year recurrence rate in non-infectious posterior segment veitis post-FAi 

Justis P. Ehlers, MD, of the Cole Eye Institute at the Cleveland Clinic, speaks with 

' David Hutton on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)" during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."

Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD (ASRS 2020)

®' David Hutton on the key findings and take-aways from his presentation, "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery," during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

Daniel F. Kiernan, MD, FCS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."

Dexamethasone intracameral drug-delivery suspension in vitreoretinal surgery inflammation (ASRS 2020)



S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment, in an interview with

 Sheryl Stevenson during the virtual 2020 American Society of Retina Specialists (ASRS) meeting.

S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment

Author | Alex Delaney-Gesing

Articles

Evaluating 3-year recurrence rate in non-infectious posterior segment veitis post-FAi

Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD (ASRS 2020)

Dexamethasone intracameral drug-delivery suspension in vitreoretinal surgery inflammation (ASRS 2020)

How one surgeon is integrating recent retina advances in COVID-19 (ASRS 2020)